Sanofi gets Swiss clearance for obesity drug

Acomplia is indicated in association with a light hypocaloric diet and physical activity for obese patients, or for overweight patients with at least one associated cardiovascular risk factor. The drug should be given after insufficient weight reduction following physical activity or alimentary adaptation.

Acomplia is the first member of a therapeutic class, the CB1 receptor antagonists. The market authorization is based on an analysis of the safety and efficacy results and the assessment of a phase III clinical trial program. These results have shown that Acomplia at 20mg per day significantly reduces weight.